Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

Peter Nash; Iain B McInnes; Philip J Mease; Howard Thom; Matthias Hunger; Andreas Karabis; Kunal Gandhi; Shephard Mpofu; Steffen M Jugl

doi:10.1007/s40744-018-0117-3

Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

Rheumatol Ther. 2018 Dec;5(2):595. doi: 10.1007/s40744-018-0117-3.

Authors

Peter Nash¹, Iain B McInnes², Philip J Mease³, Howard Thom⁴, Matthias Hunger⁵, Andreas Karabis⁶, Kunal Gandhi⁷, Shephard Mpofu⁸, Steffen M Jugl⁸

Affiliations

¹ University of Queensland, Brisbane, QLD, Australia. drpnash@tpg.com.au.
² University of Glasgow, Glasgow, UK.
³ Swedish Medical Center and University of Washington, Seattle, WA, USA.
⁴ University of Bristol, Bristol, UK.
⁵ MAPI Group, Munich, Germany.
⁶ MAPI Group, Houten, The Netherlands.
⁷ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
⁸ Novartis Pharma AG, Basel, Switzerland.

Abstract

Under Methods section, heading Analyses: Pairwise Comparisons, one of the probability value was published incorrectly in a sentence. The correct sentence should read as follows.

Publication types

Published Erratum